Results 101 to 110 of about 10,848 (199)

Supplementary Figure S6 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells

, 2021
The in vivo antitumor effect of obinutuzumab in SU-DHL-4 cells transplanted mouse xenograft model.
Yoriko Yamashita-Kashima (15088800), Natsumi Kawasaki (15088803), Yasushi Yoshimura (6553670), Shigeki Yoshiura (15088806), Naoki Harada (1822495), Takaaki Fujimura (15088797)   +5 more
core   +1 more source

Efficacy and safety of obinutuzumab as rescue therapy for rituximab-resistant and rituximab-recurrent primary membranous nephropathy: a retrospective cohort study

Open Medicine
With the recognition of membranous nephropathy as an autoimmune disease, targeting B-cells has emerged as an effective therapeutic agent for primary membranous nephropathy (PMN).
Tian Li, Pei Huaying, Dong Tianhua, Zhou Mengsi, Li Shaomei, Zhao Xi, Liang Xuzhi, Xing Lingling   +7 more
doaj   +1 more source

Impact of obinutuzumab alone and in combination for follicular lymphoma

, 2017
Maryam Sarraf Yazdy, Bruce D Cheson Division of Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA Abstract: Although rituximab-based chemoimmunotherapy prolongs the survival of patients ...
Sarraf Yazdy M, Cheson BD
core  

Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial

Drug Design, Development and Therapy
Background Membranous nephropathy (MN) can cause nephrotic syndrome. B cells contribute to MN, but available treatments are often inadequate. We addressed this treatment gap by analyzing the effect of obinutuzumab in patients with primary MN (PMN ...
Xue-qi Li, Yang Liu, Ze-Yu Cai, Tie-Gang Lv, Jian Hao   +4 more
semanticscholar   +1 more source

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors

Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco, Stefania Bramanti, Paolo Corradini, Enrico Derenzini, Pier Luigi Zinzani   +4 more
wiley   +1 more source

Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Oncology and Therapy
Introduction Compared with chemoimmunotherapy, both zanubrutinib monotherapy and venetoclax plus obinutuzumab prolong progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL). Matching-adjusted indirect comparison (MAIC) can be
Talha Munir, Nicolás Martinez-Calle, Sheng Xu, Keri Yang, Xiaoyun Ge, Ayad K. Ali, Leyla Mohseninejad, Balázs Dobi, Pal Rakonczai, Han Ma, Rhys Williams, Wassim Aldairy, Nicole Lamanna   +12 more
doaj   +1 more source

Rescue with Obinutuzumab and Daratumumab as Combined B-cell/Plasma Cell Targeting Approach in Severe Post-Transplant FSGS Recurrence.

American Journal of Transplantation
The recurrence of primary focal segmental glomerulosclerosis (FSGS) after kidney transplantation is associated with a high graft loss rate with standard treatments based on plasmapheresis with/without rituximab.
Paolo Randone, Enrico Sanna, Caterina Dolla, E. Gallo, S. Mingozzi, Rita Tarragoni, M. C. Torazza, Anna Niarchos, A. Mella, A. Manzione, A. Barreca, I. Deambrosis, R. Giraudi, Luigi Biancone   +13 more
semanticscholar   +1 more source

Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study

Virology Journal
Background Patients treated with anti-CD20 monoclonal antibodies could have a higher risk of adverse outcomes of coronavirus disease 2019 (COVID-19). The novel anti-CD20 monoclonal antibody obinutuzumab has shown greater B-cell depletion and superior in ...
Wenxiu Shu, Qianqian Yang, Jing Le, Qianqian Cai, Hui Dai, Liufei Luo, Jiaqi Tong, Yanping Song, Bingrong Chen, Dengbing Chen, Dian Jin   +10 more
doaj   +1 more source

A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease

Journal of Clinical Oncology
PURPOSE The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard-of-care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wild-type TP53; however, due ...
M. Davids, C. Ryan, B. Lampson, Yue Ren, S. Tyekucheva, Stacey M. Fernandes, J. Crombie, A. Kim, Matthew Weinstock, J. Montegaard, H. Walker, Claire Greenman, V. Patterson, C. Jacobson, A. LaCasce, Philipe Armand, David C. Fisher, Steve Lo, A. Olszewski, J. Arnason, Inhye E. Ahn, Jennifer R. Brown   +21 more
semanticscholar   +1 more source

Successful management of belimumab after obinutuzumab in a patient with systemic lupus erythematosus: a case report with an 18-month follow-up

Frontiers in Immunology
IntroductionSystemic lupus erythematosus (SLE) is a complex autoimmune disease, and despite the availability of multiple treatments, striking a balance between long-term efficacy and side effects remains a major clinical challenge.
Xiuxiu Pu, Xiuxiu Pu, Qiao Ye, Lin Zhu, Lin Zhu, Tingting Yan   +5 more
doaj   +1 more source